1. ALLA AKTIER
  2. NYHETER
  3. BBS-BIOACTIVE BONE SUBSTITUTES

BBS-Bioactive Bone Substitutes

Nyheter BBS-Bioactive Bone Substitutes Nyheter alla bolag

BBS-Bioactive Bone Substitutes – Insider information: The company updates the status of the CE marking process

MARKN.

BBS-Bioactive Bone Substitutes Plc | Company Release | May 05, 2024 at 21:30:00 EEST

Insider information: The company updates the status of the CE marking process

Based on the available information, the company estimates that the CE marking process will not be completed by the end of the second quarter in 2024 as previously estimated. The process is at a stage where the company has submitted the required information for product registration to the authorities.

During these final phases of the process, the company will no longer provide an exact time estimate for the completion of the CE marking process, as the company can no longer influence the processing schedules of the authorities.

The product's journey towards commercialization (updated)

PhaseActionStatus
Product developmentPreclinical animal testsCompleted

Functionality and efficiency testsCompleted

Clinical testCompleted



CE markingSubmitting the CE applicationCompleted

Quality system applicationApproved

1st auditCompleted

2nd auditCompleted

Additional auditCompleted

Additional measuresCompleted

Product approvalIn process

Product classificationCompleted

Consultation with the Medicines AgencyIn process

Production lines and line certificationIn process



CommercializationPreliminary commercializationIn process

Extensive commercializationIn preparation

Previously published announcements related to the CE marking application

  • November 25, 2023 – The Notified Body has approved the Company’s quality system
  • November 2, 2023 – Insider information: The company provides an update on the CE marking process related to the approval of the quality system – consultation with the Finnish Medicines Agency to begin on 21 November 2023
  • September 13, 2023 – Insider information: Plan to complete minor open issues approved – the Company updates its outlook on the schedule of the CE marking
  • August 31, 2023 – Inside information: The final report of the additional audit received from the Notified Body
  • May 26, 2023 – Inside information – Positive decision received on the product classification, schedule for the quality system approval to be updated
  • March 27, 2023 – Inside information: The final report of the second audit received from the Notified Body, the CE marking process may continue and CE marking approval continues to be expected during 2023
  • December 30, 2022 – Insider information: BBS updates the estimate of the CE marking approval schedule of ARTEBONE® Paste
  • November 18, 2022 – Inside information: The first audit completed by the Notified Body, CE marking process may continue as planned
  • March 9, 2022 – BBS Bioactive Bone Substitutes Plc has filed the CE-marking application of Artebone® bone void filler to the authorities

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes – Insider information: The company updates the status of the CE marking process

Datum 2024-05-05, kl 20:30
Källa MFN
Bifogade filer
BBS-Bioactive Bone Substitutes – Insider information: The company updates the status of the CE marking process
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!